Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Notes Payables (2017 - 2021)

ProQR Therapeutics' Notes Payables history spans 2 years, with the latest figure at $5.5 million for Q4 2021.

  • On a quarterly basis, Notes Payables rose 303.32% to $5.5 million in Q4 2021 year-over-year; TTM through Dec 2021 was $5.5 million, a 303.32% increase, with the full-year FY2021 number at $5.6 million, up 317.22% from a year prior.
  • Notes Payables hit $5.5 million in Q4 2021 for ProQR Therapeutics, down from $21.5 billion in the prior quarter.
  • Over the last five years, Notes Payables for PRQR hit a ceiling of $21.5 billion in Q1 2021 and a floor of $1.4 million in Q4 2020.